Biologic grafts such as bovine pericardium are widely used in cardiovascular, reconstructive, and neurosurgical procedures. While strength, flexibility, and handling are critical factors, low immunogenicity — the ability to avoid triggering an immune response — is equally important for the long-term success of the graft.
In this article, we explain what immunogenicity is, why it matters, and how modern processing of bovine pericardium reduces it to safe levels.
🧬 What Is Immunogenicity?
Immunogenicity refers to the ability of a substance (like a graft) to provoke an immune response in the body. When the immune system recognizes foreign proteins or cells, it may respond with inflammation, tissue rejection, or graft degradation.
In the context of biologic grafts, high immunogenicity can lead to:
- Chronic inflammation
- Calcification of the graft
- Degradation or structural failure over time
- Poor healing or integration
🧪 Why Biologic Grafts Are Processed
Biologic materials, like bovine pericardium, contain cells, proteins, and antigens that the human body may recognize as foreign. To reduce this risk, grafts are processed through:
- Decellularization: Removing all animal cells to minimize antigen content
- Chemical fixation: Stabilizing the collagen matrix, often with glutaraldehyde
- Sterilization and washing: Removing remnants that could trigger immune reactions
These steps reduce the graft’s immunogenic profile while maintaining its biomechanical properties.
✅ Benefits of Low-Immunogenic Bovine Pericardium
- Reduced inflammation post-implantation
- Better long-term integration into host tissues
- Lower risk of graft failure or rejection
- Improved durability and reduced need for reoperation
- More predictable healing with less scarring or encapsulation
🏥 Clinical Importance
In cardiac surgery, where the graft must withstand high pressure and long-term function, immune rejection can be catastrophic. That’s why surgeons prioritize biologic materials with proven biocompatibility and low immunogenicity.
Patients with autoimmune conditions or those on immunosuppressive therapy are especially sensitive to biologic implants. Low-immunogenic products minimize complications in these high-risk groups.
🌍 Regulatory Perspective
To ensure low immunogenicity, medical authorities (such as the FDA or CE authorities) require thorough testing of all biologic products, including:
- Residual DNA testing
- Histological analysis
- Immune marker assays
- In vivo biocompatibility studies
Only products that meet strict standards are approved for clinical use.
🔬 The Future: Non-crosslinked and Next-Gen Grafts
While glutaraldehyde has long been the standard for reducing immunogenicity, newer techniques — such as non-crosslinked pericardium, enzymatic treatments, and low-temperature preservation — are emerging to preserve tissue quality while further minimizing immune response.